Maternal-child health benefits of optimizing vitamin D status during pregnancy may include a reduced risk of pre-eclampsia, improved fetal growth and beneficial effects on infant immune function. These hypotheses require evaluation by randomized controlled antenatal vitamin D supplementation trials using doses that are high enough to elevate serum 25-hydroxyvitamin D concentrations into the range believed to be associated with improved health outcomes. Such doses may be considerably higher than the current recommended dietary allowance (600 IU day There have been no published reports of the teratogenic effects of vitamin D on humans. Some animal studies have suggested the potential for dosedependent fetal toxicities (for example, growth impairment, skeletal malformations and cardiovascular anomalies), but the relevance of these observations to humans is unknown. Antenatal vitamin D supplementation trials should incorporate a range of methods for objectively establishing maternal and fetal safety, and aim to identify the lowest doses of vitamin D required to achieve target outcomes.
Introduction
Enthusiasm for the broad health benefits of optimal vitamin D status in adults has generated numerous hypotheses regarding the potential maternal and child health outcomes that may accompany improvements in vitamin D status during pregnancy, including prevention of pre-eclampsia, 1 improved fetal growth and enhanced infant immunological development. [2] [3] [4] [5] The trials of antenatal vitamin D supplementation published since 1980 have generally lacked sufficiently rigorous designs and outcome measures necessary for the development of dietary guidelines or risk assessment (Supplementary online Table 1 ). A Cochrane Collaboration review concluded that there was a lack of evidence to recommend vitamin D supplementation during pregnancy, 6 and the Institute of Medicine suggests that pregnant women attain the same recommended dietary allowance of vitamin D as nonpregnant adults (15 mg ¼ 600 IU day -1 ) and not exceed the tolerable upper intake level of 4000 IU day -1 (ref. 8 Dose-response studies in nonpregnant adults have revealed that oral vitamin D doses severalfold higher than the recommended dietary allowance may be required to ensure elevations of [25(OH) D] to at least 80 nmol l -1 in a majority of the population. 9 This is the [25(OH)D] threshold above which some investigators belive there to be optimal intestinal absorption, maximal suppression of parathyroid hormone (PTH) secretion, fracture and falling prevention in the elderly and possibly other multisystem effects including cancer and cardiovascular risk reduction. [10] [11] [12] Although the evidence for the benefits of [25(OH)D] >80 nmol l -1 has been questioned by the recent Institute of Medicine panel on vitamin D, 7 trials of maternal antenatal vitamin D supplementation should ideally employ daily or intermittent vitamin D3 doses high enough to attain steady-state [25(OH)D] >80 nmol l -1 in at least one group of participants, to avoid null findings that result from inadequate dosing rather than a true absence of biological effect.
The study of antenatal vitamin D supplementation regimens requires careful attention to safety issues, because: (1) the safety of exposing pregnant women and fetuses to exogenous (supplemental) vitamin D cannot be directly extrapolated from studies involving children or non-pregnant adults; (2) (4) the mechanisms of vitamin D toxicity cannot be assumed to be exclusively mediated by dysregulation of maternal or fetal calcium homeostasis or be entirely quantifiable by conventional indicators of vitamin D toxicity (that is, hypercalcemia and hypercalciuria). 13 To inform the design and interpretation of supplementation trials, this review aimed to critically address the known and theoretical causes and consequences of maternal or fetal vitamin D toxicity based on published animal and human studies of vitamin D supplementation during pregnancy (see Supplementary Information online for literature search strategy, approach to data abstraction and outline of primary data sources). The review is structured as a set of five questions that may be considered by investigators planning antenatal vitamin D supplementation studies and by clinicians who will need to interpret trial data expected to be published in the near future. The discussion relates primarily to vitamin D supplementation among generally healthy pregnant women, and may not apply to patients with underlying medical conditions that affect the vitamin D-PTH endocrine system. Question 1: during maternal antenatal vitamin D supplementation, can increases in maternal circulating vitamin D metabolite concentrations lead to abnormal fetal calcium metabolism, even in the absence of maternal vitamin D toxicity? Vitamin D is absorbed from the intestine, synthesized in the skin, or drawn from stores in adipose tissue. The most comprehensively understood metabolic pathway is that vitamin D is hydroxylated in the liver to 25(OH)D, which is subsequently hydroxylated in the kidney to 1,25-dihydroxyvitamin D (1,25(OH)D), the most biologically active vitamin D receptor (VDR) ligand. VDR activation in the skeleton and intestine is directly involved in the regulation of the serum calcium concentration. The clinical and pathological features of severe vitamin D intoxication in humans are attributable to acute or chronic hypercalcemia, which is therefore the most widely accepted biochemical criterion for vitamin D toxicity. A current theory to explain the mechanism of vitamin D-induced hypercalcemia is that excessively high circulating concentrations of 25(OH)D (and vitamin D itself) can displace 1,25(OH)2D from the vitamin D-binding protein (DBP), leading to excessive free (unbound) 1,25(OH)2D, and thereby causing hypercalcemia by stimulating unfettered calcium absorption and bone resorption.
14 Based on the experiences of women with primary hyperparathyroidism, hypercalcemia during pregnancy is known to cause substantial maternal and fetal morbidity, and a high risk of intrauterine death. 15 Maternal vitamin D status and serum calcium concentration can be readily monitored to identify vitamin D regimens that cause maternal hypercalcemia in association with elevated 25(OH)D concentrations; regimens that cause maternal hypercalcemia in even a small minority of women would be precluded from use in routine clinical or public health practice. However, because circulating fetal concentrations of vitamin D metabolites and calcium are not easily measured, a key question is whether fetal hypercalcemia can arise in the absence of maternal hypercalcemia.
Animal studies. Rat studies have revealed that fetal vitamin D stores are acquired via transplacental transfer of vitamin D metabolites during the third trimester of gestation. 16 In rats, 25(OH)D readily crosses into the fetal circulation, but 1,25(OH)2D does not seem to cross to a significant degree. 17 As well, 1-a-hydroxylation of 25(OH)D to 1,25(OH)2D in the fetal kidneys is regulated independently of maternal vitamin D status, and is relatively suppressed in the fetus. 18 Fetal [1,25(OH)2D] likely remains low because the transplacental unidirectional calcium flow that maintains physiological fetal 'hypercalcemia' relative to the maternal circulation is primarily regulated by PTH-related protein, 19 and perhaps PTH. 20 Calcium flux does not greatly depend on the VDR in mice, 21 yet it has been observed that pharmacological maternal doses of 1,25(OH)2D increased placental calcium flow in sheep. 22 29 in which the final mean maternal serum calcium concentration ([Ca]) in a group of women assigned to receive 1000 IU vitamin D2 per day in the third trimester was not only higher than the control group, but was at the upper limit of the normal range, suggesting that episodes of hypercalcemia may have occurred despite not being mentioned by the authors. Nonetheless, it is notable that the mean cord [Ca] did not differ between the vitamin D and control groups, and both group means were well within the normal range for venous cord blood (see Supplementary online Table 2 ). As discussed in a later section, the reported maternal and cord 25(OH)D responses to the vitamin D intervention in the Brooke trial strongly suggest that participants were exposed to a vitamin D dose much higher than reported.
In 10 published controlled antenatal vitamin D supplementation studies, 8 of 10 vitamin D-control comparisons showed that vitamin D led to higher mean cord [Ca] , and in 3 comparisons the difference was reported as statistically significant [30] [31] [32] [33] (Supplementary online Table 2 ). Higher postnatal [Ca] (that is, 2 to 6 days of life) occurred in the vitamin D groups in all seven comparisons where values were reported; five of these differences were reported as statistically significant. 29, 30, 34, 35 Mean cord [Ca] were within the normal range in all groups in these studies (Supplementary online Table 2 ). Neither the incidence of hypercalcemia nor ranges of values were specifically reported in any of the randomized studies. However, given that two trials showed a significantly reduced risk of neonatal hypocalcemia in the vitamin D group, 29, 35 it is likely that observed increases in mean [Ca] represented the normalization of deficiencies that may occur in the first week of life, during which there is a physiological nadir in neonatal calcium concentration. In one single-arm trial in which a one-time dose of 2 mg D3 was administered at 27 to 32 weeks of gestation, arterial cord blood [Ca] above the reference range were observed in most infants, but neonatal venous specimens 3 to 5 days later were normal in all. 36 The authors concluded that the intervention was safe, but the significance of the findings is difficult to ascertain given the absence of a control group.
In studies of very high-dose vitamin D treatment of pregnant women with hypoparathyroidism, 37 [Ca] , but this appears to represent a therapeutic effect on populations at high risk of vitamin D deficiency. In the setting of intense vitamin D exposures, fetuses appeared to be protected against the development of hypercalcemia, particularly in the absence of maternal hypercalcemia. However, prospective trials published to date have not adequately reported maternal or fetal/ infant [Ca] ranges or risks of hypercalcemia in normal pregnancies. As well, there is a paucity of data on the effects of oral cholecalciferol (vitamin D3), the compound produced in the skin in response to ultraviolet radiation, as opposed to plant-derived ergocalciferol (vitamin D2).
In antenatal vitamin D trials, maternal serum [Ca] is a key safety parameter to be monitored. Serum total calcium concentration declines during pregnancy, coincident with plasma volume expansion and a reduction in the serum albumin concentration. 39 When feasible, the ionized calcium should be measured; however, when total calcium is measured, values can be corrected for the serum albumin concentration, and compared with published reference values for pregnancy. 40 The incidence of hypercalcemia using prespecified cutoffs, not just the mean [Ca], should ideally be reported.
Question 2: following a large oral bolus dose of vitamin D3, can a rapid increase in the maternal serum vitamin D3 concentration cause toxicity via a transiently unregulated increase in the serum 1,25(OH)2D concentration? High-dose vitamin D3 regimens involving single or intermittent doses several orders of magnitude larger than daily doses are appealing because of the potential for improved adherence. However, because such doses cause a rapid peak in serum vitamin D concentrations in addition to a rise in serum [25(OH)D], 41 it is important to consider the potential for hypercalcemic crisis in the first few days following dose administration.
Animal studies. The key rate-limiting enzyme in vitamin D metabolism is 1a-hydroxylase (1a-OHase), which converts the dominant circulating metabolite, 25(OH)D, to the primary active metabolite, 1,25(OH)2D. Under physiological conditions, renal 1a-OHase functions below its saturation point, and 1,25(OH)2D synthesis is proportional to the 25(OH)D input; however, it was observed in rats that 1a-OHase activity is suppressed within 1 day of a large increase in 25(OH)D availability, 42 thus preventing a sustained increase in the [1,25(OH)2D] when [25(OH)D] is chronically elevated. 43 Yet, transient elevation of 1,25(OH)2D could occur following a large sudden input of 25(OH)D, before 1a-OHase activity is dampened.
Human studies. It is well accepted that 1a-OHase is tightly regulated in normal human adults. 44 Three recent clinical studies in non-pregnant adults provided empiric evidence that large single vitamin D3 doses up to 7.5 mg do not provoke transient hypercalcemia because of elevations in 1,25(OH)2D before 1-OHase activity is appropriately inhibited. Ish-Shalom et al. 45 documented a rise in both serum 25(OH)D and 1,25(OH)2D concentrations 1 day following a single dose of 1.125 mg of vitamin D3, but these changes were not accompanied by a rise in serum [Ca] . Ilahi et al. 46 found that serum [Ca] did not rise in the first 5 days following a single vitamin D3 dose of 2.5 mg, and Romagnoli et al. 47 likewise did not find any increase in serum [Ca] after administering 7.5 mg (E Romagnoli, personal communication). However, Cipriani et al. 48 recently reported that a single bolus vitamin D3 dose of 15 mg in young adults induced a significant increase in the mean serum calcium concentration on day 3, coincident with a peak mean 1,25(OH)2D concentration. Unfortunately, the range of values and incidence of hypercalcemia were not described. Several other studies of large bolus D3 doses of up to 12.5 mg have not adequately studied the changes in serum calcium in the first week after dose administration. [49] [50] [51] Furthermore, the recent finding of an increased risk of falls and fractures among older women following annual oral bolus doses of 12.5 mg vitamin D3 has heightened concern about the potential harms of single-dose regimens. 50 In summary, vitamin D3 doses up to 7.5 mg do not appear to produce disturbances in calcium homeostasis in non-pregnant adults. However, the overall safety of large bolus doses is not well established, and there is evidence of potential harm of doses >7.5 mg.
As mentioned earlier, the concentration of free 1,25(OH)2D rather than total 1,25(OH)2D is increased in the setting of vitamin D toxicity; 52 this is believed to be a consequence of 1,25(OH)2D displacement from the DBP by other vitamin D metabolites. 53 Therefore, a second consideration in the setting of a large single dose of D3 is that a sudden rise in circulating D3 and 25(OH)D could displace 1,25(OH)2D from the DBP, thus increasing the concentration of free (bioactive) 1,25(OH)2D. In a seminal study in which rats were exposed to graded doses of D3, the minimum dose that provoked hypercalcemia was associated with vitamin D metabolite concentrations that collectively exceeded the rat DBP (at an average [25(OH)D] of 1600 nmol l -1 ); 54 analogous observations have been made in humans with vitamin D toxicity.
14 During pregnancy, the approximate capacity of the DBP to bind vitamin D metabolites is 8300 nmol l -1 , almost double the binding capacity in non-pregnant adults. 55 Even under non-pregnant conditions, the DBP capacity exceeds by at least sevenfold the peak aggregate concentration of vitamin D metabolites after a single dose of 2.5 mg vitamin D3. 46 Doses required to attain a target [25(OH)D]>80 nmol l À1 are unlikely to be high enough to produce vitamin D toxicity by displacement of 1,25(OH)2D from DBP.
Question 3: does extra-renal vitamin D metabolism during pregnancy create hypersensitivity to exogenous vitamin D3 relative to the non-pregnant state? Over the past 20 years, 1,25(OH)2D synthesis in tissues other than the kidney has been described. 56 In contrast to the tight regulation of human renal 1a-OHase activity, extra-renal 1a-OHase is not subject to analogous feedback mechanisms. For example, in patients with granulomatous diseases (for example, sarcoidosis), in which there is substantial extra-renal expression of 1a-OHase, serum concentrations of 1,25(OH)2D rise dramatically in response to oral vitamin D administration. 57 Decidualplacental expression of 1a-OHase throughout pregnancy raises the possibility of heightened sensitivity to increases in circulating [25(OH)D] during pregnancy. 58 The regulation of placentaldecidual vitamin D metabolism is only beginning to be described, 59 but in direct contrast to the feedback mechanism in the kidney, the 1a-OHase may in fact be downregulated by PTH.
60 Uterine 1a-OHase was shown to be upregulated by specific cytokines, 61 consistent with the notion of an autocrine/paracrine regulatory mechanism.
Pregnancy is associated with a progressively elevated total serum [1,25(OH)2D]. Most of the evidence from humans point toward the relative abundance of 1,25(OH)2D being primarily of maternal renal rather than placental or fetal origin. 18, 62, 63 Because the rise in [1,25(OH)2D] is accompanied by a proportional increase in DBP secondary to elevated estrogen production, its implications for calcium homeostasis or other VDR-dependent processes have not been established. 64 Although there are conflicting findings as to whether or not the bioactive free [1,25(OH)2D] is increased relative to the non-pregnant state, 65, 66 there is evidence that the proportion of free 1,25(OH)2D significantly increases in the last month of term pregnancy, 67 a period that correlates with increased transplacental calcium transfer to the fetus. The apparent variation in 1,25(OH)2D metabolism throughout gestation underscores the notion that responsiveness to exogenous vitamin D may be modified by the gestational age at which supplementation occurs.
To explore the potential pregnancy-induced vitamin D hypersensitivity, data from published antenatal vitamin D supplementation trials (Supplementary online 70 have logically inferred that the vitamin D preparation used in this study must have contained more vitamin D than labeled.
An additional consideration in antenatal supplementation trial design is the physiological increase in total urinary calcium excretion that occurs during pregnancy. This does not appear to predispose pregnant women toward urinary calculi formation, 71 perhaps because of the concomitant increase in excretion of urinary inhibitors of stone formation (for example, citrate and magnesium). 72 However, it is unknown whether pregnant women are at heightened risk of pathological hypercalciuria secondary to increases in antenatal vitamin D intake.
In summary, exaggerated 1,25(OH)2D responses to oral vitamin D during pregnancy appear unlikely, but the available literature contain insufficient evidence to conclude whether or not pregnancy in general, or specific gestational stages, cause vitamin D hypersensitivity. Until further data are reported, recent reviews that have concluded that vitamin D toxicity-related hypercalcemia in non-pregnant adults is unlikely to occur at vitamin D doses <250 mg day -1 (<10 000 IU day -1 ) or [25(OH)D] <240 nmol l -1 (ref. 10, 73) provide guidance for the design of antenatal vitamin D trials. However, the tolerability of previously untested supplementation doses should be established in nonpregnant women of reproductive age before application to pregnant women. Where feasible, direct comparisons of pregnant and nonpregnant women should be undertaken, and particular attention may be given to monitoring the effects of vitamin D on urinary calcium excretion and the risk of stone formation.
Although the focus of this review is on safety rather than efficacy, it is worthwhile noting that aside from the aberrant finding of Brooke et al., 29 none of the vitamin D interventions reported in prospective antenatal studies have been effective in raising the mean [25(OH)D] at delivery into the range proposed as optimal (>80 nmol l -1 ), even with daily doses of 1000 IU day -1 or large single doses of 2.5 mg (100 000 IU) vitamin D3 in the third trimester. Thus, as would be expected based on studies in nonpregnant adults, cumulative doses during pregnancy substantially >2.5 mg (for example, >1200 IU per day in the third trimester) may be required to attain a maternal-fetal vitamin D status hypothesized to be optimal. Question 4: even if a particular dose of vitamin D does not cause hypercalcemia, can exogenous vitamin D3 be metabolized to form toxic compounds via pathways other than 25-hydroxylation? Ingested vitamin D3 is absorbed from the intestinal lumen into the circulation via incorporation into chylomicrons that enter the lymphatic system. The process appears to be nonsaturable, unregulated by hormonal feedback mechanisms and affected primarily by the absorption of dietary fat. 74 Absorbed vitamin D3, transported in serum primarily by the DBP, can be considered to have four possible fates: (1) Although 25-hydroxylation is not known to be regulated by endocrine feedback inhibition, a constraint on hepatic 25-hydroxylation has been observed, whereby excess circulating D3 is shunted into tissue stores or metabolized when the capacity of the hepatic 25-hydroxylases is exceeded. 77, 78 Vitamin D entering the blood via the gastrointestinal route reaches the liver faster than vitamin D endogenously produced in the skin, 79 suggesting a higher risk that 25-hydroxylase function will be overwhelmed and alternative metabolites will be formed following oral vitamin D ingestion in comparison with D3 generated by sun exposure. 80 Recent data suggest that saturation of hepatic 25-hydroxylation activity occurs when the steady-state serum D3 concentration reaches B15 nmol l -1 , above which D3 accumulates in tissues faster than it is 25-hydroxylated. 41 Unsupplemented individuals without abundant sun exposure have circulating D3 levels much lower than this threshold.
Human subjects administered exogenous 25(OH)D3 had incremental rises in serum [25(OH)D] that were up to 12-fold higher than those attained with similar doses of D3. 77 , 81 Vieth 82 has concluded that a large proportion of D3 must be excreted or metabolized by routes other than 25-hydroxylation; this would be consistent with observations that vitamin D activity in bile was believed to be because of the presence of vitamin D metabolites other than 25(OH)D or D3. 83 However, few modern studies have measured the total bioavailability of ingested vitamin D compounds, limiting our understanding about the long-term contribution of tissue-deposed D3 to circulating 25(OH)D versus other metabolites. In a recent analysis of the kinetics of 25-hydroxylation, Heaney et al. 41 used estimates of a modelindependent measure of bioavailability (area under the curve) for both D3 and 25(OH)D to infer that virtually all of the D3 absorbed from a single dose of 2.5 mg vitamin D3 in adults was eventually converted to 25(OH)D within 4 months. This finding suggested that excretion or degradation of orally administered vitamin D3 occurs downstream of hepatic 25-hydroxylation, and that production of non-25-hydroxylated metabolites may be negligible.
Nevertheless, there remains uncertainty about the extent to which vitamin D may be converted to non-25-hydroxylated metabolites, raising the theoretical potential for toxic effects via alternative pathways. Although vitamin D3 itself is believed to be biologically inactive, there are a variety of non-25-hydroxylated metabolites that have been derived from the D3 parent molecule. 84 For example, secosteroids resulting from a 20-hydroxylation reaction catalyzed by cytochrome P450 side chain cleavage enzyme 85 are biologically active in vitro (for example, promote keratinocyte differentiation). 86 Theoretical implications in the setting of pregnancy are of interest because P450 side chain cleavage enzyme is expressed at high levels in the placental tissue. 87 In addition, photoisomers of vitamin D3 (for example, tachysterol) have antiproliferative properties that may not be mediated via the VDR. 88 In summary, it is unlikely that non-25-hydroxylated metabolites of vitamin D3 occur in biologically significant concentrations following oral vitamin D3 ingestion. However, observations to date permit speculation that very large doses of vitamin D3 could lead to non-negligible concentrations of alternative metabolites not detected by monitoring serum [25(OH)D], and which may have biological effects unrelated to calcium homeostasis. The clinical significance of such metabolites during pregnancy has not been studied, and indeed presents significant research challenges. Tables 4 and 5 ). In rats, overt fetal or placental toxicity (that is, growth restriction, impaired osteogenesis, placental damage and mortality) occurred at cumulative vitamin D doses during pregnancy of 26 to 90 mg kg -1 , but not at doses p5.2 mg kg -1 . Although the teratogenic effects in these studies were dose dependent, they were not clearly mediated by maternal or fetal hypercalcemia. Dose-dependent adverse antenatal effects have also been observed in rabbits. Cumulative doses of X4.7 mg kg -1 caused systemic fetal toxicity (growth restriction and high mortality), but cumulative doses as low as 0.88 mg kg -1 caused noncalcified vascular lesions in offspring, even in the absence of obvious alterations in calcium regulation (Supplementary online Table 4 ). A tenfold lower dose of 0.088 mg kg -1 did not cause the vascular lesions, yet still was associated with poor maternal weight gain. However, in rabbits, serum calcium levels vary widely, are generally much higher than other mammals (up to B3.75 mmol l -1 ) and rise proportionately with dietary calcium, which is passively absorbed independently of vitamin D. 89 These distinctions highlight the difficulty in defining hypercalcemia in the rabbit, and suggest that adverse effects may occur at lower weight-adjusted vitamin D doses than those that might cause toxicity in humans. In cows, B1 mg kg -1 D3 administered within the month before calving was associated with severe hypercalcemic toxicity; the adverse effects on offspring were not described (Supplementary online Tables 4 and 5 ). Whereas pregnant rats have been observed to be relatively resistant to vitamin D toxicity compared with non-pregnant rats administered equivalent doses, pregnant cows were found to be more susceptible to vitamin D toxicity than non-pregnant cows (Supplementary  online Tables 4 and 5) .
It is important to mention a series of studies in rabbits and rats published in the 1960 to 1980s that reported specific craniofacial and aortic abnormalities in the offspring of dams given extremely high doses of vitamin D (Supplementary online Tables 4 and 5 ). The earliest of these studies fueled the propagation of an otherwise unsubstantiated association between vitamin D intake and Williams syndrome, a condition in humans characterized by facial dysmorphism, infantile hypercalcemia and supravalvular aortic stenosis, now known to be caused by a mutation in the elastin gene. 95 Similar animal studies have not been reported in more than 2 decades, and the relevance of the original findings to vitamin D supplementation in humans remains highly questionable.
Two animal studies merit mention because although they involved relatively low vitamin D doses that were not apparently hypercalcemic, they perpetuated hypotheses about potentially adverse cardiovascular effects of prenatal vitamin D. Norman et al. 90 exposed pregnant rats to three graded dietary vitamin D3 intake levels within the range normally consumed, which were continued in the offspring for 6 weeks postnatally. Aortic histology was normal in all rat pups and there were no significant differences in aortic dimensions or any occurrence of supravalvular aortic stenosis; however, there was a vitamin D dose-dependent decrease in mean concentrations of aortic elastic lamellae and higher peak aortic wall tension in the offspring (Supplementary  online Tables 4 and 5 ). These findings were consistent with more recent observations that 1,25(OH)2D caused abnormal elastin deposition in smooth muscle cell culture. 91 Although serum calcium concentrations were not reported by Norman et al., 90 the doses were in a range that is non-hypercalcemic in rats, 43 and all rat pups had serum [25(OH)D] considered normal in humans. A limitation was that the overall feed intake in the rats in the control group was double that of the highest vitamin D group, suggesting that dietary differences other than vitamin D intake could have influenced the findings. 92 In a study by Toda et al., 93 unknown quantities of 'high' or 'low' amounts of vitamin D administered to two pregnant sows resulted in normal [25(OH)D] in the offspring, but marginally higher percentages of lipid-containing or degenerated smooth muscle cells in the coronary arteries of the five piglets born to the sow given the 'high' vitamin D diet compared with the six piglets born to the sow given the 'low' vitamin D diet (Supplementary online Tables 4 and 5 ). In addition to their substantial methodological limitations, the observations in the studies of Norman et al. 90 and Toda et al.
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reflect anatomic or histological variations rather than defined pathology, and raise hypotheses but do not inform human dose selection. More recent laboratory data point toward adverse cardiovascular effects of fetal/neonatal vitamin D deficiency. In a recent rat study, offspring born to dams fed a vitamin D-depleted diet had relatively hypertrophic and hyperplastic left cardiac ventricles at 4 weeks of age compared with offspring of dams fed normal vitamin D-replete diets, 94 indicating that antenatal vitamin D sufficiency may be important for improving cardiovascular outcomes in the offspring.
Human studies. The literature search did not yield any published reports of teratogenic effects attributed to antenatal vitamin D supplementation in humans. There were no reports of adverse clinical or morphological fetal effects in prospective trials in which up to 1200 IU per day or 1.2 million IU as large ('pulse') intermittent doses of vitamin D were administered to women in the third trimester of normal pregnancies (Supplementary online  Table 1 ). However, few of these trials have rigorously reported safety-related outcomes; as noted above, the reporting of biochemical indicators of toxicity has been insufficient for risk assessment (for example, the proportion of supra-normal values of cord blood [Ca] have not often been reported), and the rigorous measurement of adverse clinical outcomes has been largely unaddressed.
The adverse effects attributable to vitamin D have not been found among infants born to women with hypoparathyroidism treated with vitamin D2 at doses up to 200 000 IU per day (Supplementary online Table 3 ). To put these doses in perspective, they are >100-fold higher than the doses used in the trials, and represent cumulative intakes that are even higher than some of the doses that apparently caused severe toxicities in animal models. Transplacental transfer of 25(OH)D likely caused very high fetal [25(OH)D], which was documented in one of the cases; 38 thus, the lack of congenital anomalies in the offspring suggests that supranormal fetal concentrations of vitamin D metabolites were not directly harmful. There was also a notable absence of adverse effects in an infant whose healthy mother had taken 10 000 IU day -1 vitamin D for the first 2.5 weeks of gestation, 96 the period of greatest vulnerability to teratogenesis. Furthermore, congenital anomalies have not been caused by antenatal administration of synthetic calcitriol (1,25(OH)2D), 97 the current standard treatment for hypoparathyroidism. These observations are in contrast to the high rate of adverse pregnancy outcomes 98 and fetal anomalies 99 that occur in untreated or poorly controlled maternal hypoparathyroidism. Finally, with respect to the debunked notion that vitamin D intake causes Williams syndrome, it is important to highlight that in retrospect, there never existed any clinical or epidemiological evidence that maternal antenatal vitamin D intake was associated with this condition. [100] [101] [102] [103] A major barrier to drawing inferences from published trials and case series regarding the safety of antenatal vitamin D supplementation is that almost all studies have involved vitamin D2 rather than D3. Although D2 may have up to a tenfold lower potency than D3, 69 the transport and metabolism of D2 involves pathways distinct from those typically involved in D3 metabolism, which may render D2 more likely to yield toxic effects. 9, 104 In what may be the only report of human toxicity associated with antenatal ingestion of a vitamin D-containing compound, findings published in the Ohio State Medical Journal in 1937 suggested that unquantified doses of 'viosterol' (ergosterol irradiated to yield ergocalciferol) were associated with higher rates of placental and fetal calcifications compared with cod liver oil (a rich source of cholecalciferol), which led to outcomes similar to those in the control group. 105 However, the literature search for this review did not uncover any studies that have directly compared D2 and D3 during pregnancy. Nonetheless, with the increasing availability of D3 supplements, and the relatively undesirable properties of D2, 104 there is no foreseeable advantage to using D2 in future antenatal supplementation studies.
In summary, observations in some animal species suggest the potential for dose-dependent adverse fetal effects of maternal vitamin D intake, but toxicity thresholds differ between species and cannot be extrapolated to humans. Lesions observed in rat and rabbit offspring were not clearly caused by maternal hypercalcemia, did not appear as typical calcified lesions, were not necessarily associated with elevated [25(OH)D] and occurred at cumulative vitamin D doses lower than those associated with systemic fetal toxicity (for example, growth restriction) (Supplementary online Table 4 ). Cumulative exposures in human pregnancies at a similar order of magnitude as those considered toxic in some animals have not reportedly caused fetal anomalies. Implications of published animal studies for the design of human supplementation trials thus remain very limited.
Conclusion
Human studies published to date suggest that antenatal vitamin D supplementation may be safe at doses several fold higher than the current recommended dietary allowance recently set by the Institute of Medicine (2010), 7 but there are insufficient data to establish specific low-risk antenatal vitamin D intake levels. In fact, there are scant published data to specifically justify the Institute of Medicine panel's decision to apply the generic tollerable upper intake level of 4000 IU per day to pregnant women. Although animal studies have shown dose-dependent maternal toxicity and teratogenesis, there are considerable limitations in extrapolating such findings to humans, in whom adverse fetal effects have not reportedly occurred following maternal ingestion of maintenance doses as high as 5 mg (200 000 IU) D2 per day. The consideration of various mechanisms by which antenatal vitamin D supplementation at higher than recommended doses may cause harm underscores the researcher's imperative to be vigilant about the monitoring and anticipation of potential adverse events in clinical trials (Supplementary online Table 6 ).
The following considerations in the design and interpretation of antenatal supplementation trials are proposed:
(1) Vitamin D3 should be studied at doses lower than those that can cause adverse alterations in calcium metabolism in nonpregnant adults (for example, <250 mg day ), 73 and that are established to be well tolerated by non-pregnant women of reproductive age in the target population. Vitamin D3 is preferable over D2, because of the latter's potentially lower efficacy and theoretically increased risk of toxicity. 104 As pharmacological data about D2 do not inform D3 dose selection, and commercial supplements increasingly contain D3, studies using D2 are expected to have limited generalizability in the future. (2) There is a need for trials to compare different supplementation frequencies, not just dose ranges. Large intermittent pulse doses would be a potentially more feasible public health approach than daily supplementation, but their safety and efficacy needs to be specifically evaluated. (3) Biomarkers of calcium metabolism remain the most important indicators of vitamin D toxicity, even though it is not certain that all forms of toxicity are mediated by hypercalcemia. Calcium metabolism is best assessed by measurement of maternal serum calcium concentrations (ionized or albuminadjusted total calcium), and cord blood calcium concentrations should also be documented. Serum calcium measurements should be timed in accordance with what is known about vitamin D pharmacology (for example, after a single large dose of vitamin D3, the highest risk of hypercalcemia is expected within the first month). Urinary calcium excretion is conventionally monitored to screen for hypercalciuria, which theoretically precedes hypercalcemia in the setting of vitamin D toxicity. 9 A progressive increase in absolute urinary calcium excretion is normally observed during pregnancy, 106 but appears to be a result of an increased glomerular filtration rate, such that the fractional excretion of calcium remains constant. 107 Therefore, it is appealing to use a biomarker that is adjusted for physiological changes in glomerular filtration rate, such as the calcium/creatinine ratio. However, as the upper limit of the normal range is not well established for pregnancy, a more reliable interpretation of this outcome is through a between-group comparison of means during the supplementation period. Vitamin D status (that is, [25(OH)D]) is not itself a safety biomarker, as the upper limit of normal is not well established. Other biomarkers of vitamin D and calcium metabolism (for example, PTH, 1,25(OH)2D concentration, alkaline phosphatase and serum phosphorus) may help to interpret changes in serum calcium, but are unlikely to have implications for routine safety monitoring. Renal function testing should be performed in the setting of hypercalciuria or hypercalcemia. There is no rationale for routinely performing invasive fetal sampling to measure fetal calcium or vitamin D metabolite concentrations, unless such a procedure is being performed for a specific clinical indication. (4) To address the theoretical risk of adverse effects occurring in the absence of maternal hypercalcemia, investigators should consider incorporating general indicators of maternal and fetal health (for example, maternal weight gain, prenatal ultrasonography, maternal blood pressure, gestational age at birth and birth anthropometry), even if these are not primary efficacy outcomes. Infants born to women who received experimental antenatal doses of vitamin D should undergo detailed physical examinations to document major and minor congenital anomalies. In trials using high, previously unstudied dose regimens, consideration should be given to more detailed organ-specific investigations (for example, infant echocardiography to assess aortic structure). Efforts should be made to conduct long-term follow-up of infants born to women administered high antenatal doses of vitamin D, with particular consideration toward neurodevelopmental indices and cardiovascular function. Consideration should be given to basic and clinical research that will promote a greater understanding of the physiological activity of non-25-hydroxylated vitamin D metabolites during pregnancy. (5) Trials should be conducted among various target populations, recognizing that geography, composition of the local food supply, nutritional status and genetics are likely to modify safety outcomes.
Several antenatal vitamin D trials are underway, or recently concluded. Hollis' group has recently completed a randomized trial in South Carolina in which pregnant women were randomized to 400, 2000 or 4000 IU day -1 vitamin D3. Preliminary data presented at conferences indicated an absence of hypercalcemia or other adverse events at these doses. 108 We have recently completed data collection in a preliminary antenatal vitamin D3 dose-finding and safety study in Bangladesh. Using doses of up to 35 000 IU per week in the third trimester, there was an absence of supplement-related adverse effects (Roth et al., unpublished observations). A larger randomized trial is currently underway in Dhaka (NCT01126528). The safety considerations reviewed here are intended to help clinicians to contextualize the interpretation of these and other trials expected to be published over the next several years.
Bearing in mind the U-or J-shaped hormetic dose-response curves that represent the balance between a nutrient's benefits and harms, 109 antenatal vitamin D supplementation research should proceed cautiously, aiming to expose pregnant women to an amount of supplemental vitamin D sufficient to achieve an optimal vitamin D status and anticipated public health benefits (for example, reduced risk of low birth weight, improved immune function and so on), but within a range that will be safe for population-based application.
